Various phenotypes of LRBA gene with compound heterozygous variation: A case series report of pediatric cytopenia patients.

Jiafeng Yao, Hao Gu, Wenjun Mou, Zhenping Chen, Jie Ma, Honghao Ma, Nan Li, Rui Zhang, Tianyou Wang, Jin Jiang, Runhui Wu
{"title":"Various phenotypes of <i>LRBA</i> gene with compound heterozygous variation: A case series report of pediatric cytopenia patients.","authors":"Jiafeng Yao,&nbsp;Hao Gu,&nbsp;Wenjun Mou,&nbsp;Zhenping Chen,&nbsp;Jie Ma,&nbsp;Honghao Ma,&nbsp;Nan Li,&nbsp;Rui Zhang,&nbsp;Tianyou Wang,&nbsp;Jin Jiang,&nbsp;Runhui Wu","doi":"10.1177/03946320221125591","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>LPS-responsive beige-like anchor (LRBA) deficiency is one of the most common monogenic disorders causing common variable immunodeficiency (CVID) and CVID-like disorders. However, the clinical spectrum of compound heterozygous (CHZ) LRBA variation should be extended. In this study, we presented five cases of compound heterozygous LRBA with various refractory cytopenias.</p><p><strong>Materials and methods: </strong>Retrospective analysis of the clinical manifestations, management, and outcomes of five cases (from five pedigrees) with <i>LRBA</i> gene CHZ variants which initially manifested as single/multilineage immune cytopenias was performed.</p><p><strong>Results: </strong>1. Gene variations: All five patients inherited the compound heterozygous LRBA variations from their parents which were thought to be pathogenic. BEACH, DUF4704, and LamG were the main affected domains of LRBA gene in this case series. 2. Immune dysregulation of clinic: (1) Hypogammaglobulinemia were recorded in four patients, and the proportion of Treg was decreased in two patients. Only one patient had been with increased TCRαβ+CD4/CD8 double-negative T cells (DNT). (2) Lymphoproliferative manifestations were seen in three patients. (3) All five patients were complained with cytopenia, although they showed different clinical manifestations. None of the parents was asymptomatic. (4) Other immune disorders: P5 also had relapsed infections and autoimmune endocrinopathy. 3. Management and outcomes: P1 and P5 responded well to immunomodulatory therapy and P3 was effectively treated with hemophagocytic lymphohistiocytosis (HLH) first-line regimen chemotherapy. P4 showed no responses to steroids and IVIG. However, TPO-R agonist was effective.</p><p><strong>Conclusion: </strong>Unlike homozygous mutations, compound heterozygous LRBA variation should always be kept in mind for the various phenotypes and different treatment responses.</p>","PeriodicalId":14046,"journal":{"name":"International Journal of Immunopathology and Pharmacology","volume":"36 ","pages":"3946320221125591"},"PeriodicalIF":3.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4f/fb/10.1177_03946320221125591.PMC9465590.pdf","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Immunopathology and Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03946320221125591","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: LPS-responsive beige-like anchor (LRBA) deficiency is one of the most common monogenic disorders causing common variable immunodeficiency (CVID) and CVID-like disorders. However, the clinical spectrum of compound heterozygous (CHZ) LRBA variation should be extended. In this study, we presented five cases of compound heterozygous LRBA with various refractory cytopenias.

Materials and methods: Retrospective analysis of the clinical manifestations, management, and outcomes of five cases (from five pedigrees) with LRBA gene CHZ variants which initially manifested as single/multilineage immune cytopenias was performed.

Results: 1. Gene variations: All five patients inherited the compound heterozygous LRBA variations from their parents which were thought to be pathogenic. BEACH, DUF4704, and LamG were the main affected domains of LRBA gene in this case series. 2. Immune dysregulation of clinic: (1) Hypogammaglobulinemia were recorded in four patients, and the proportion of Treg was decreased in two patients. Only one patient had been with increased TCRαβ+CD4/CD8 double-negative T cells (DNT). (2) Lymphoproliferative manifestations were seen in three patients. (3) All five patients were complained with cytopenia, although they showed different clinical manifestations. None of the parents was asymptomatic. (4) Other immune disorders: P5 also had relapsed infections and autoimmune endocrinopathy. 3. Management and outcomes: P1 and P5 responded well to immunomodulatory therapy and P3 was effectively treated with hemophagocytic lymphohistiocytosis (HLH) first-line regimen chemotherapy. P4 showed no responses to steroids and IVIG. However, TPO-R agonist was effective.

Conclusion: Unlike homozygous mutations, compound heterozygous LRBA variation should always be kept in mind for the various phenotypes and different treatment responses.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
复合杂合变异LRBA基因的多种表型:儿童细胞减少症病例系列报道。
目的:脂多糖反应性米色锚蛋白(LRBA)缺乏症是引起常见可变免疫缺陷(CVID)和CVID样疾病的最常见的单基因疾病之一。然而,复合杂合(CHZ) LRBA变异的临床谱还有待扩大。在本研究中,我们报告了5例复合杂合LRBA合并各种难治性细胞减少症。材料与方法:回顾性分析5例(来自5个家系)LRBA基因CHZ变异患者的临床表现、处理及转归,这些患者最初表现为单/多系免疫性细胞减少症。结果:1。基因变异:所有5例患者都从父母那里遗传了复合杂合LRBA变异,这被认为是致病的。BEACH、DUF4704和lam是本病例系列LRBA基因的主要影响结构域。2. 临床免疫失调:(1)4例患者出现低γ -球蛋白血症,2例患者Treg比例下降。仅有1例患者TCRαβ+CD4/CD8双阴性T细胞(DNT)升高。(2) 3例患者出现淋巴细胞增生性表现。(3) 5例患者均以细胞减少为主诉,但临床表现不同。没有父母是无症状的。(4)其他免疫疾病:P5还存在复发性感染和自身免疫性内分泌病变。3.治疗和结果:P1和P5对免疫调节治疗反应良好,P3接受噬血细胞淋巴组织细胞增多症(HLH)一线方案化疗有效。P4对类固醇和IVIG无反应。然而,TPO-R激动剂有效。结论:与纯合突变不同,复合杂合LRBA变异具有不同的表型和不同的处理反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.00
自引率
0.00%
发文量
88
审稿时长
15 weeks
期刊介绍: International Journal of Immunopathology and Pharmacology is an Open Access peer-reviewed journal publishing original papers describing research in the fields of immunology, pathology and pharmacology. The intention is that the journal should reflect both the experimental and clinical aspects of immunology as well as advances in the understanding of the pathology and pharmacology of the immune system.
期刊最新文献
Resveratrol promotes the differentiation of human umbilical cord mesenchymal stem cells into esophageal fibroblasts via AKT signaling pathway Clinical role of NDRG2-based methylation status on survival pattern of glioblastoma A novel immune cell signature for predicting glioblastoma after radiotherapy prognosis and guiding therapy Low-dose metformin suppresses hepatocellular carcinoma metastasis via the AMPK/JNK/IL-8 pathway Macrophage-derived exosomal miRNA-141 triggers endothelial cell pyroptosis by targeting NLRP3 to accelerate sepsis progression
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1